SAN RAMON, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced a poster was presented on the Company's NeuVax™ (nelipepimut-S) investigator-sponsored Phase 2 clinical trial (IST) in high-risk, HER2 3+ patients at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC. The Phase 2 trial is a multi-center, prospective, randomized, single-blinded, placebo-controlled trial combining NeuVax and trastuzumab in the adjuvant setting to prevent recurrence in HER2-positive (HER2 3+) breast cancer patients. The poster, entitled, " Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients," presented the interim safety analysis that was initiated after enrollment of the 50 th patient in the trial (vaccine group (VG) n=22, control group (CG) n=28). The analysis demonstrated that the agent is well tolerated with no increased cardiotoxicity associated with giving NeuVax in combination with trastuzumab. In the trial, there were no significant clinicopathologic differences between groups. The vast majority of toxicities were grade 1 and there were no related grade 4 or 5 toxicities and no differences in related toxicities between the VG and CG (Grade 1: 96% vs 98.5%; Grade 2: 3.2% vs 1.5%; Grade 3: 0.8% vs 0%, p=0.14). There was no significant reduction in cardiac ejection fraction (EF) pre- to post-treatment in either group (VG: 61.1±5.4% vs 60.1±4.8%, p=0.55; CG: 62.3±5.7% vs 61.9±4.0%, p=0.74) and no notable difference in EF was observed between the baseline (pre-treatment) and the follow-up (post treatment) within the vaccine and control groups (p=0.54). "As we reported in February, this data was the basis for the Data Safety Monitoring Board (DSMB) to perform a futility analysis and recommend the study continue as planned. Additionally, the DSMB determined that there were no safety concerns," said Bijan Nejadnik, M.D., Executive Vice President and Chief Medical Officer. "The poster presented at AACR provides a more detailed safety analysis of the ongoing IST with NeuVax in combination with trastuzumab in HER2 positive breast cancer patients. We are pleased that the combination of agents are well tolerated and that there is no additive cardio toxicity."